Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
163
resultados
Última actualización
04/08/2026 [06:55:00]
Resultados 150 a 163 de 163
Resumen de: US20260157702A1
0000 Control device (30) for determining an amount of carbohydrate (RC) recommendation. The control device comprises a retrieving unit (32), the retrieving unit (32) being configured to retrieve user data, an outlier unit (34), the outlier unit (34) being configured to determine whether a user data is considered to be an outlier or not, an RC unit (36), the RC unit (36) being configured to estimate an RC recommendation using mathematical functions of the user data; and a transmission unit (38), the transmission unit (38) being configured to transmit the RC recommendation. The transmission unit (38) is configured to transmit the RC recommendation if and only if the last user data is not considered to be an outlier.
Resumen de: US20260158217A1
A diabetes management system including a wearable device having an elongated support patch with an adhesive disposed on a skin side, a sensor portion disposed on a non-skin side and including an electrochemical glucose sensor and a wireless communication module, and a medication delivery portion disposed on a non-skin side and comprising a medication reservoir and a medication pump. The system also includes a behavior tracking device having a tracking wireless communication module, a portable electronic device configured to communicate wirelessly to the wearable device and the behavior tracking device, and a controller. The sensor portion is configured to detect a glucose level of a subject and the controller is configured to receive the glucose level and to transmit to the medication pump an instruction which causes the medication pump to deliver a dose to the subject of a medication based on the glucose level.
Resumen de: WO2026119866A1
The present invention relates to a computer-implemented method for predicting a risk for a subject to experience an analyte concentration in a bodily fluid above a predetermined glucose event threshold at the end of a predetermined predicting time interval, a data processing system, a computer program, a system, and remote control. The disclosure, thus, relates to the management of diabetes. The risk is predicted based on a plurality of input parameters and using a machine learning model.
Resumen de: US20260159864A1
0000 A standardized plant extract is produced by cultivating undifferentiated or differentiated in vitro cultures of Haberlea rhodopensis Friv. (HR), followed by harvesting the biomass and extracting bioactive compounds and primary and secondary metabolites, including organic acids, fatty acids, amino acids, sterols, free phenols, sugars, and polyphenols. The extraction process is performed under controlled conditions to yield an extract with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract. The extract may be combined with glycerol to form a composition with standardized myconoside content. The resulting extract or biomass is then incorporated into products for the pharmaceutical, cosmetic, or food industries. This method provides a consistent, renewable, and sustainable source of raw material, eliminating dependence on wild plant populations and seasonality, and delivers valuable health-protective properties.
Resumen de: US20260158171A1
The disclosure provides insulin-glucagon-like peptide 1 (GLP-1) polynucleotides for delivery to pancreatic islet cells, as well as compositions comprising the polynucleotides and methods of treating obesity-associated metabolic disorders.
Resumen de: US20260157662A1
The device for dynamic determination of a slow insulin dose to be injected comprises: a means (21) of acquiring multiple blood glucose levels during a first day and the day following the first day,a means (26) of calculating the difference in blood glucose levels,a means (22, 24, 25, 42, 43) of determining if a predetermined event has occurred between going to bed and getting up,a means (26) of determining, if no predetermined event has occurred, a hyperglycaemia or a hypoglycaemia depending on the difference in blood glucose levels,a means (26) of determining if at least a predetermined number of hyperglycaemias or hypoglycaemias have occurred in a predetermined period of time,a means (26) of modifying the slow insulin to be injected, in this case of an occurrence, anda means (25) of indicating a numerical value of the modified slow insulin dose to be injected.
Resumen de: WO2026120569A1
A system includes a wearable device and a charger case. The wearable device is configured to be positioned on an ear of a wearer, and includes first and second body portions and a connection member mechanically coupled to each of the first body portion and the second body portion. The first body portion and/or the second body portion includes a processor, a memory, and a sensor set including at least one of a pulse oximeter, a photoplethysmogram (PPG) sensor, an accelerometer, a temperature sensor, a proximity sensor, an ambient light sensor, or a gyroscopic sensor. The memory stores instructions to cause the processor to calculate at least one of a blood oxygen saturation level, a pulse rate, a blood pressure level, a blood flow rate, a cardiac output/rhythm, a blood sugar level, a blood carbon monoxide level, a blood nitrous oxide level, or an electrocardiogram of the wearer.
Resumen de: WO2026120503A1
The technology provides a system and method for assessing loss of vibration perception in a subject. It may be useful for the self-diagnosis, self-monitoring and self-treatment of adverse health conditions such as cutaneous neuropathy or diabetic foot, and for developing related prognoses. The system comprises a wearable or handheld vibration device which includes piezoelectric elements. These may be actuated to produce vibrations which are transmitted to the body surface of the subject by a probe. A communications apparatus is provided so that data can be transferred between the vibration device and a computing device such as a smartphone. The computing device is arranged to control levels of intensity of vibration of the piezoelectric elements, to record data representing levels of intensity of vibration, and to record and track input data entered by the user, corresponding to levels of intensity of vibration at which the subject perceives the transmitted vibrations via their body surface.
Resumen de: EP4756833A1
The invention discloses a diabetes management system for use in a hospital, including: at least a wearable medical device, a plurality of receivers, a central server and a healthcare provider terminal, the receivers receive the data information transmitted by the medical device and upload it to the central server, and the healthcare provider communicates with the central server and displays or reviews the medical data information through the terminal, as any one of the multiple receivers can receive the data information transmitted by the medical device and upload it to the central server, as a result, the patient's range of motion in the hospital is no longer restricted, which improves the patient's experience and keeps the patient in a comfortable mood, while the healthcare provider is able to know the patient's blood glucose level and/or insulin infusion state in real time through the healthcare provider terminal and deal with the abnormalities in a timely manner, so that the patient's blood glucose level can be maintained at a stable level.
Resumen de: WO2025029671A1
Disclosed herein are methods of treating a subject having diabetes with a population of cells expressing ISL1 and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety.
Resumen de: US2025049355A1
Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor and convert the sensor current generated by the continuous analyte sensor into digital signals, one or more processors configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.
Resumen de: EP3831293A1
The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.
Nº publicación: PL2794857T3 08/06/2026
Solicitante:
JANSSEN BIOTECH INC [US]
Janssen Biotech, Inc.
Resumen de: PH12014501429A1
The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10 pcnt of the cells in the population express markers characteristic of single hormonal pancreatic beta cells.
BOPI
Sede Electrónica
